Advertisement

Picture EBD Group Global Partnering Four Events One Price 650x80

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in the Nordic Countries, Denmark, Finland, Iceland, Norway and Sweden, or involving organisations from these countries.

Total search results: 659 | Ordered by Date (descending)
1 2 3 4 5 6 7  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Mobidiag–Hologic: investment, 202104– acquisition €600m in cash ANNOUNCED 2021-04-08
Step Pharma–Hadean Ventures: investment, 202103 financing round Series B totalling €35m incl new + co-lead investor Hadean Ventures 2021-03-24
Step Pharma–SEVERAL: investment, 202103 financing round Series B €35m co-led by new investors Hadean Ventures + Sunstone Life Science Ventures 2021-03-24
Step Pharma–Sunstone Life Science: investment, 202103 financing round Series B totalling €35m incl new + co-lead investor Sunstone Life Science 2021-03-24
Aura Biosciences–SEVERAL: investment, 202103 financing round $80m led by Matrix Capital Management + Surveyor Capital 2021-03-22
Cellink–SEVERAL: credit, 202103–202603 convertible bonds SEK1.5b at 2.875%pa convertible into B Class shares at SEK598.5/share 2021-03-12
Cellink–SEVERAL: investment, 202103 capital increase SEK1.5b directed issue of new Class B Shares at SEK420/share 2021-03-12
MatTek–Cellink: investment, 202103– acquisition $68m net of cash/debt with $54.4m in cash + $13.6m in shares ANNOUNCED 2021-03-10
BioPhero–DCVC: investment, 202103 financing round Series A totalling $17m incl new + lead investor DCVC Bio 2021-03-09
BioPhero–FMC: investment, 202103 financing round Series A totalling $17m incl new + co-investor FMC Ventures 2021-03-09
BioPhero–Novo Group: investment, 202103 financing round Series A totalling $17m incl existing + co-investor Novo Holdings 2021-03-09
BioPhero–SEVERAL: investment, 202103 financing round Series A $17m led by DCVC Bio with FMC Ventures + Syngenta Ventures + Novo Holdings 2021-03-09
BioPhero–Syngenta: investment, 202103 financing round Series A totalling $17m incl existing + co-investor Syngenta Ventures 2021-03-09
Exscientia–BlackRock: investment, 202103 financing round Series C extension totalling $40m + closing at total of $100m incl new investor BlockRock 2021-03-04
Exscientia–SEVERAL: investment, 202103 financing round Series C extension $40m + closing at total of $100m with BlockRock joining existing investors 2021-03-04
Oxular–NeoMed: investment, 202103 financing round totalling £27m incl existing + co-investor NeoMed 2021-03-01
Oxular–SEVERAL: investment, 202103 financing round £27m led by Forbion 2021-03-01
Oxular–V-Bio Ventures: investment, 202103 financing round totalling £27m incl existing + co-investor V-Bio Ventures 2021-03-01
Tetramer Shop–10x Genomics: investment, 202102 acquisition €na of Tetramer Shop ApS by 10x Genomics Inc 2021-02-24
Altasciences–Novo Group: investment, 202102– acquisition of Altasciences by Novo Holdings from Audax Private Equity ANNOUNCED 2021-02-22
Almirall–MC2 Therapeutics: Wynzora Cream, 202102– license excl to commercialise Wynzora Cream for plaque psoriasis in Europe for Almirall 2021-02-17
Cognate BioServices–Charles River: investment, 202102– acquisition $875m in cash by Charles River ANNOUNCED 2021-02-17
Ginolis–Cellink: investment, 202102–202103 acquisition 100% of Ginolis debt/cash-free for €65.7m with €41.6m in cash + €24.1m in shares 2021-02-15
EnginZyme–SEB: investment, 202102 financing round Series A extension totalling €4.6m incl new + co-investor SEB Greentech VC 2021-02-11
EnginZyme–SEVERAL: investment, 202102 financing round Series A extension €4.6m led by Industrifonden + incl SEB Greentech VC + existing shareholders 2021-02-11
EnginZyme–Sweden (govt): investment, 202102 financing round Series A extension totalling €4.6m incl new + lead investor Industrifonden 2021-02-11
Evaxion Biotech–LifeSci: public relations, 202102 supply service existent by LifeSci Advisors LLC 2021-02-10
Evaxion Biotech–SEVERAL: investment, 202102 US IPO $30m+$4.5m with 3m+450k ADSs at $10/ADS at Nasdaq Capital Market 2021-02-10
IO Biotech–Avoro Capital: investment, 202101 financing round Series B totalling €127m incl new + co-investor Avoro Capital 2021-01-13
IO Biotech–Eurazeo: investment, 202101 financing round Series B totalling €127m incl new + co-investor Idinvest Partners 2021-01-13
IO Biotech–HBM: investment, 202101 financing round Series B totalling €127m incl new + lead investor HBM Healthcare Investments 2021-01-13
IO Biotech–Kurma: investment, 202101 financing round Series B totalling €127m incl new + co-investor Kurma Partners 2021-01-13
IO Biotech–Lundbeck: investment, 202101 financing round Series B totalling €127m incl existing+ co-investor Lundbeckfonden Emerge 2021-01-13
IO Biotech–Novo Group: investment, 202101 financing round Series B totalling €127m incl existing+ co-investor Novo Seeds 2021-01-13
IO Biotech–PFM Health Sciences: investment, 202101 financing round Series B totalling €127m incl new + co-investor PFM Health Sciences 2021-01-13
IO Biotech–RA Capital: investment, 202101 financing round Series B totalling €127m incl new + co-investor RA Capital Management 2021-01-13
IO Biotech–Samsara BioCapital: investment, 202101 financing round Series B totalling €127m incl new + co-investor Samsare BioCapital 2021-01-13
IO Biotech–Serrado Capital: investment, 202101 financing round Series B totalling €127m incl new + co-investor Serrada Capital 2021-01-13
IO Biotech–SEVERAL: investment, 202101 financing round Series B €127m led by new investor HBM Healthcare Investments 2021-01-13
IO Biotech–Soleus Capital: investment, 202101 financing round Series B totalling €127m incl new + co-investor Soleus Capital 2021-01-13
IO Biotech–Sunstone Life Science: investment, 202101 financing round Series B totalling €127m incl existing+ co-investor Sunstone Life Science 2021-01-13
IO Biotech–Vivo Capital: investment, 202101 financing round Series B totalling €127m incl new + co-investor Vivo Capital 2021-01-13
BioGeneration Ventures–Industriens Pension: investment, 202101 final closing of BGV IV totalling €140m incl investor Industriens Pension 2021-01-07
BioGeneration Ventures–Novo Group: investment, 202101 final closing of BGV IV totalling €140m incl investor Novo Ventures 2021-01-07
BioGeneration Ventures–SEVERAL: investment, 202101 final closing of BGV IV with €140m incl Lilly + Novo Ventures + BMS + Schroder Adveq et al 2021-01-07
CorWave–Novo Group: investment, 202101 financing round Series C totalling €35m incl existing + co-investor Novo Holdings 2021-01-06
CorWave–SEVERAL: investment, 202101 financing round Series C €35m led by new investor EIC Fund 2021-01-06
Faron Pharmaceuticals–Precision Medicine Group: public relations, 202101 service existent IR by Stern IR 2021-01-04
Immunicum–Van Herk: investment, 202012c largest shareholder holding 43% after merger of Immunicum with DCprime 2020-12-31
Hemab–Genmab: antibody technology, 202012 existent license to DuoBody platform to develop antibodies for bleeding disorders 2020-12-14
Hemab–Novo Group: antibody technology, 202012 existent license to IP to develop antibodies for bleeding disorders from Novo Nordisk AS 2020-12-14
Hemab–Novo Group: investment, 202012 seed investor Novo Seeds 2020-12-14
Evaxion Biotech–EU (govt): credit, 202012– EIB loan €20m under InnovFin program to advance AI-based vaccine research 2020-12-09
BioInnovation Institute–Novo Group: grant, 202012–203012 up to €470m funding over ten years to BBI from Novo Nordisk Foundation 2020-12-08
Single Technologies–SEVERAL: investment, 202012 financing round €5m oversubscribed share issue with existing + new investors 2020-12-04
Enduro Genetics–BioInnovation Institute: credit, 202012 pre-seed loan €470k from BII 2020-12-02
Slack Technologies–Salesforce: investment, 202012– acquisition $27.7b in cash + shares of Slack by Salesforce ANNOUNCED 2020-12-01
SynOx Therapeutics–Odlander Fredrikson: investment, 202011 financing round Series A totalling €37m incl co-lead investor HealthCap 2020-11-19
SynOx Therapeutics–SEVERAL: investment, 202011 financing round Series A €37m co-led by HealthCap + Medicxi with Forbion + Gimv 2020-11-19
BioInvent–Van Herk: investment, 202011 existent Van Herk is largest shareholder of BioInvent 2020-11-18
DCprime–Immunicum: investment, 202011– merger with former Immunicum shareholders holding 56% + Van Herk holding 43% of combined company ANNOUNCED 2020-11-18
Synendos Therapeutics–SEVERAL: investment, 202011 financing round Series A CHF20m co-led by Kurma Partners + Sunstone LSV 2020-11-12
Emisphere–Novo Group: investment, 202011– acquisition of Emisphere by Novo Nordisk for $1.35b in cash on a cash/debt-free basis 2020-11-06
The Protein Brewery–SEVERAL: investment, 202011 financing round Series A €22m led by Novo Holdings 2020-11-03
Monocl–Definitive Healthcare: investment, 202010 acquisition of Monocl by Definitive Healthcare LLC 2020-10-29
Galecto–LifeSci: public relations, 202010 supply service existent media contact LifeSci Advisors 2020-10-28
Galecto–SEVERAL: investment, 202010 US IPO $85m+12.75m with 5.67m+850k common stock shares at $15/share 2020-10-28
Kaffe Bueno–Denmark (govt): investment, 202010 seed financing round totalling €1.1m incl investor Vaekstfonden 2020-10-27
Kaffe Bueno–OTHER: investment, 202010 seed financing round totalling €1.1m incl a Danish business angel as investor 2020-10-27
Kaffe Bueno–Paulig Group: investment, 202010 seed financing round totalling €1.1m incl investor PINC 2020-10-27
Kaffe Bueno–SEVERAL: investment, 202010 seed financing round €1.1m from PINC + Vaekstfonden + The Yield Lab + a Danish business angel 2020-10-27
Kaffe Bueno–Yield Lab: investment, 202010 seed financing round totalling €1.1m incl investor The Yield Lab IE 2020-10-27
Prokarium–Flerie Invest: investment, 202010 financing round Series B totalling $21m incl co-investor Flerie Invest (FF) 2020-10-27
Prokarium–SEVERAL: investment, 202010 financing round Series B $21m led by Korea Investment Partners 2020-10-27
VectivBio–SEVERAL: investment, 202010 crossover financing $110m from existing + new investors 2020-10-15
Oncopeptides–EU (govt): credit, 202010– unsecured €40m loan facility in three tranches with each 5y maturity from EIB 2020-10-14
Rappta Therapeutics–Advent Venture Partners: investment, 202010 financing round Series A totalling €9m incl co-investor Advent Life Sciences 2020-10-13
Rappta Therapeutics–Novartis: investment, 202010 financing round Series A totalling €9m incl co-lead investor Novartis Venture Fund 2020-10-13
Rappta Therapeutics–Novo Group: investment, 202010 financing round Series A totalling €9m incl co-lead investor Novo Seeds 2020-10-13
Rappta Therapeutics–Optimum Strategic Communications: public relations, 202010 service existent by Optimum 2020-10-13
Rappta Therapeutics–OTHER: investment, 202010 financing round Series A totalling €9m incl a family office as co-investor 2020-10-13
Rappta Therapeutics–SEVERAL: investment, 202010 financing round Series A €9m co-led by NVF + Novo Seeds 2020-10-13
Priothera–Odlander Fredrikson: investment, 202010 financing round Series A totalling €30m incl co-lead investor HealthCap 2020-10-12
Priothera–SEVERAL: investment, 202010 financing round Series A €30m led by Fountain Healthcare Partners 2020-10-12
Rare Thyroid Therapeutics–PledPharma: investment, 202010–202011 acquisition of RTT for SEK60m + 63.77m new shares + milestones 2020-10-05
Galecto–SEVERAL: investment, 202009 financing round $64m led by Soleus + co-lead by Eir Ventures 2020-09-25
Jennewein Biotechnologie–Chr. Hansen: investment, 202009– acquisition €310m on debt-free basis ANNOUNCED 2020-09-22
Sundew–Novo Group: investment, 202009 seed financing round totalling €1.4m inkl DKK10m (€1.34m) from Novo Nordisk BII 2020-09-22
Sundew–SEVERAL: investment, 202009 seed financing round €1.4m with €1.34m from Novo Nordisk BII + €85k from StartLife 2020-09-22
Sundew–StartLife (NL): investment, 202009 seed financing round totalling €1.4m inkl €85k from StartLife 2020-09-22
Lava Therapeutics–Novo Group: investment, 202009 financing round Series C totalling $83m incl new + co-lead investor Novo Ventures 2020-09-17
Lava Therapeutics–SEVERAL: investment, 202009 financing round Series C $83m co-led by Novo Ventures + Sanofi Ventures 2020-09-17
Umotif–SEVERAL: investment, 202009 financing round Series A £5m led by existing investor AlbionVC 2020-09-03
Cartana–10x Genomics: investment, 202008 acquisition of Cartana AB by 10x Genomics Inc 2020-08-31
Scienion–Cellink: investment, 202008– acquisition €80m on cash/debt-free basis with €40m in shares + €40m in shares 2020-08-19
Genkyotex–Calliditas Therapeutics: investment, 202008– acquisition in two steps for €32.3m in cash + €55m milestones (contingent rights) ANNOUNCED 2020-08-13
F2G Ltd–Novo Group: investment, 202008 financing round totalling $60.8m incl exisiting investor Novo Ventures 2020-08-12
F2G Ltd–SEVERAL: investment, 202008 financing round $60.8m from new investor Cowen Healthcare Investments + existing investors 2020-08-12
Oasmia–Consilium: public relations, 202008 service existent by CSC 2020-08-10
Reapplix–Denmark (govt): investment, 202007 financing round totalling DKK150m ($22.6m) incl existing investor Vaekstfonden 2020-07-14
1 2 3 4 5 6 7  next pagenext page



Advertisement

Picture EBD Group Connector Personal Networking in Life Sciences 650x80

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture [iito] Back into Ad 650x80px

» top